Skip to content Skip to footer
Subscribe Now
Viewpoints_Kasper Roet 
VIEWPOINTS

Advancing Neurodegenerative Care: Kasper Roet from QurAlis Corporation in a Stimulating Conversation with PharmaShots

Shots:  Recently, QurAlis signed an exclusive license agreement with Lilly for QRL-204 for patients with ALS and FTD  Under the terms of the agreement, QurAlis granted Lilly an exclusive worldwide license to develop and commercialize QRL-204 and other UNC13A targeting compounds.  QurAlis received an up front payment of $45M plus an additional equity investment. The company is…
September 2, 2024

Read more

Viewpoints_Regina Fritsche-Danielson
VIEWPOINTS

AstraZeneca at ERA 2024: Regina Fritsche-Danielson in an Illuminating Dialogue Exchange with PharmaShots

Shots:  Associated with early onset and rapid progression of chronic kidney disease (CKD), APOL1 Mediated Kidney Disease dramatically affects people of African descent  AstraZeneca is developing AZD2373, the first potential precision treatment option for the treatment of AMKD with Ionis Pharmaceuticals. Recently, AZ shared promising data from the early P-I data from the MAD study …
August 26, 2024

Read more

Viewpoints_Manojkumar Bupathy
VIEWPOINTS

Advancing Cancer Therapy Delivery: Manojkumar Bupathy from Rocky Mountain Cancer Centers in Conversation with PharmaShots

Shots:  Addressing a high unmet medical need, PharmaShots had a riveting dialogue exchange with Manojkumar Bupathy from Rocky Mountain Cancer Centers  Manojkumar shared insights from the real-world study that analysed the treatment pattern and clinical outcomes in patients with locally advanced/metastatic urothelial carcinoma   The study reveals that four out of the ten patients received only…
August 20, 2024

Read more

Viewpoints_Jennifer Fernandez
VIEWPOINTS

TCOC Management in Oncology: Jennifer Fernandez from The Oncology Network in a Dialogue Exchange with PharmaShots

Shots:  Prominent oncology drugs like pembrolizumab and nivolumab were initially approved with weight-based dosing and gradually transitioned to fixed dozing. With the transformation in the dosing model, the average dose amount administered to patients increased dramatically in the Oncology Care Model  Today, at PharmaShots, we have Jennifer Fernandez from The Oncology Network, shedding light on…
August 7, 2024

Read more

ThoughtSpot_Saurabh Chaubey5
THOUGHTSPOT

How Innovative Public Relation Solutions Shape the Biopharma Industry?

Shots:   In the internet-driven world where social media shape opinions and perspectives, it is imperative for companies in the biopharma industry to leverage innovative PR solutions  PR solutions offer significant advantages for biopharma companies that help build their brand values, increase credibility amongst consumers and stakeholders, and much more  With hand-curated offerings designed especially for…
August 6, 2024

Read more

Viewpoints_Dr. Robert Rifikin
VIEWPOINTS

Establishing Safe Treatment: Dr. Robert Rifikin from Rocky Mountain Cancer Centers in Conversation with PharmaShots

Shots:  There is an average lifetime risk of getting multiple myeloma of about 1 in 103 men and 1 in 131 women in the United States  Treatment of multiple myeloma using fourth-line therapy like teclistamab can induce issues like cytokine release syndrome (CRS) and neurotoxicity   Today, at PharmaShots we have Dr. Robert Rifikin from Rocky…
August 5, 2024

Read more

Viewpoints_Gunjan Sharma
VIEWPOINTS

Redefining Care: Gunjan Sharma from The US Oncology Network in Conversation with PharmaShots

Shots:  Megestrol, an appetite stimulator is listed as an inappropriate medication based on the American Geriatrics Society (AGS) Beers Criteria and is considered a high-risk medication for elderly people by the Pharmacy Quality Alliance  In a study by the US Oncology Network, the use of megestrol was reviewed and weight gain benefits was evaluated in…
July 31, 2024

Read more

Viewpoints_Tahi Ahmadi
VIEWPOINTS

Enhancing Capabilities: Tahi Ahmadi from Genmab in a Riveting Dialogue Exchange with PharmaShots

Shots:  Recently, Genmab acquired ProfoundBio in a strategic move to strengthen its position in the ADC space. With this acquisition, Genmab gets ProfoundBio’s novel ADC technology platforms  Today, at PharmaShots, we have Tahi Ahmadi, EVP and Chief Medical Officer at Genmab, sharing insights from the recent acquisition of ProfoundBio by Genmab  With this acquisition, Genmab…
July 29, 2024

Read more

Viewpoints_Jane Chung
VIEWPOINTS

Expanding ADC Therapy: Jane Chung from Sutro Biopharma in an Engaging Conversation with PharmaShots

Shots:   Luvelta, an antibody-drug conjugate by Sutro Biopharma is designed to target FRα, expressed in ovarian cancer, developed and manufactured using the company’s proprietary cell-free technology, XpressCF   Today, at PharmaShots, we have Jane Chung, President and CEO at Sutro Biopharma, shedding on the ongoing REFRαME-O1 study evaluating luvelta   Sutro is now enrolling patients for the…
July 24, 2024

Read more

Load more